drugset / Trial / NCT05285397

Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.

NCT05285397

RandomizedParallel-groupDouble-blindTreatment

Summary

Our primary objective is to assess the effect of Liraglutide on weight loss in patients who have undergone secondary bariatric surgeries. We set out to assess if Liraglutide is a viable option to augment weight loss in said category.

Timeline

Start
2022-03-10
Primary completion
2022-09
Completion
2022-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 3 mg Subcutaneous

Indications